β-Confident-registry: aiming to be largest-ever studied cohort of cryopyrin-associated periodic syndromes (CAPS) patients. Study design and baseline characteristics

β-Confident-registry: aiming to be largest-ever studied cohort of cryopyrin-associated periodic syndromes (CAPS) patients. Study design and baseline characteristics

Bibliographic Details
Main Authors:	Hoffman H, Tilson H, Walker U, Rothenbacher D, Kuemmerle-Deschner J, Hawkins P
Format:	Article
Language:	English
Published:	BMC 2011-09-01
Series:	Pediatric Rheumatology Online Journal

Similar Items

Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry
by: Ulrich A Walker, et al.
Published: (2021-08-01)

Diagnosis and Management of the Cryopyrin-Associated Periodic Syndromes (CAPS): What Do We Know Today?
by: Tatjana Welzel, et al.
Published: (2021-01-01)

National CAPS (Cryopyrin-Associated Periodic Syndrome) Registry
by: Gallizzi R, et al.
Published: (2011-09-01)

A refractory heterogeneous Cryopyrin-Associated Periodic Syndrome (CAPS) phenotype related to <it>V198M</it> mutation responds to canakinumab - a case report
by: Kuemmerle-Deschner Jasmin B, et al.
Published: (2011-09-01)

Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS)
by: Justin Gillespie, et al.
Published: (2010-01-01)

Dosing patterns of canakinumab in patients with Cryopyrin-Associated Periodic Syndromes (CAPS): A comparative analysis of a study in Western versus Japanese patients
by: Takada H, et al.
Published: (2011-09-01)

Current approaches to diagnosis, treatment, and monitoring in patients with cryopyrin-associated periodic syndromes (CAPS)
by: S. O. Salugina, et al.
Published: (2016-06-01)

Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
by: Ori Toker, et al.
Published: (2010-05-01)

The interleukin 1 inhibitor canakinumab in the treatment of cryopyrin-associated periodic syndromes (CAPS): clinical experience
by: Svetlana Olegovna Salugina, et al.
Published: (2014-12-01)

CRYOPYRIN ASSOCIATED PERIODIC SYNDROME
by: M. Gattorno
Published: (2013-02-01)

Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up
by: Martini A, et al.
Published: (2011-09-01)

Wall-to-wall heart – The largest left atrium ever reported
by: Saikat Bhattacharjee, et al.
Published: (2021-01-01)

Cryopyrin-associated periodic syndromes (CAPS): report on two cases (Muckle-Wells syndrome (MWS) and CINCA/NOMID)
by: Kuzmina NN, et al.
Published: (2011-09-01)

Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap)
by: Leigh D Church, et al.
Published: (2008-10-01)

Systematic literature review of efficacy/effectiveness and safety of current therapies for the treatment of cryopyrin-associated periodic syndrome, hyperimmunoglobulin D syndrome and tumour necrosis factor receptor-associated periodic syndrome
by: Peter Hur, et al.
Published: (2020-08-01)

Generalized Confidence Interval for the Largest Normal Mean
by: Javad Behboodian, et al.
Published: (2008-03-01)

Optimal Confidence Interval for the Largest Normal Mean
by: Shan-Ni Wei, et al.
Published: (1999)

12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS)
by: Kümmerle-Deschner J, et al.
Published: (2008-09-01)

Cryopyrin-Associated Periodic Syndrome (CAPS) Caused by c.943A>G Variant of NLRP3 Gene: Clinical Case
by: Ivan A. Kriulin, et al.
Published: (2019-11-01)

A Retrospective Patient Chart Review and Survey in Patients with Cryopyrin-associated Periodic Syndromes Treated with Anakinra
by: Helen J. Lachmann, et al.

Optimal Confidence Interval for the Largest Exponential Location Parameter
by: Chih-Wen Lin, et al.
Published: (2000)

Association between celiac sprue and cryopyrin associated autoinflammatory disorders: a case report
by: Shamansky Eric, et al.
Published: (2007-06-01)

DIAGNOSIS AND TREATMENT OF PATIENTS WITH CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME
by: A. L. Kozlova, et al.
Published: (2015-04-01)

Dragon's paradise lost: palaeobiogeography, evolution and extinction of the largest-ever terrestrial lizards (Varanidae).
by: Scott A Hocknull, et al.
Published: (2009-09-01)

A Study on Confidence Intervals for the Largest Exponential Location Parameter
by: Yu-Sheng Liu, et al.
Published: (2004)

Optimal Confidence Interval for the Largest Mean of Correlated Normal Populations
by: Hsiu-Ling Li, et al.
Published: (2006)

Corneal response to canakinumab in cryopyrin associated periodic fever syndrome
by: Tsatos, M., et al.
Published: (2013)

Re-energising burns research: insights from the largest randomised trial ever undertaken in burn care
by: Baljit Dheansa, et al.
Published: (2018-03-01)

Unified Modeling of Familial Mediterranean Fever and Cryopyrin Associated Periodic Syndromes
by: Yasemin Bozkurt, et al.
Published: (2015-01-01)

Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis
by: J. H. Fisher, et al.
Published: (2019-11-01)

EXPERIENCE IN APPLICATION OF CANAKINUMAB IN PATIENTS WITH CRYOPYRIN-ASSOCIATED SYNDROME (SYNDROME CINCA/NOMID)
by: T. V. Sleptsova, et al.
Published: (2014-05-01)

Use of Anakinra in Patients with Cryopyrin-Associated Periodic Syndromes and Other Autoinflammatory Diseases
by: Mikhail M. Kostik
Published: (2016-12-01)

Cryopyrin‐associated periodic syndrome with inflammatory bowel disease: A case study
by: Karen N Raymond, et al.
Published: (2021-05-01)

Obvious optic disc swelling in a patient with cryopyrin-associated periodic syndrome
by: Kawai M, et al.
Published: (2013-08-01)

Interleukin-1&beta; inhibitors for the treatment of cryopyrin-associated periodic syndrome
by: Eugen Dhimolea
Published: (2011-01-01)

The NALP3/Cryopyrin-Inflammasome Complex is Expressed in LPS-Induced Ocular Inflammation
by: José F. González-Benítez, et al.
Published: (2008-01-01)

The ERN-LUNG Population Registry: Aims, Software-Implementation and First Results
by: Goebel, J., et al.
Published: (2022)

Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome
by: Pierre Quartier
Published: (2011-01-01)

Anakinra and related drugs targeting interleukin-1 in the treatment of cryopyrin- associated periodic syndromes
by: Bachove I, et al.
Published: (2014-03-01)

P2X7R/cryopyrin inflammasome axis inhibition reduces neuroinflammation after SAH
by: Sheng Chen, et al.
Published: (2013-10-01)